Sign up to save your podcasts
Or
Share Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Ocular Releases Phase 3 Data for Wet AMD Candidate Axpaxli
Ocular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology.
Learn more about your ad choices. Visit megaphone.fm/adchoices
View all episodes
By Eyewire NewsOcular Therapeutix releases its long-awaited SOL-1 phase 3 data for wet AMD drug candidate Axpaxli; Nordic Pharma expands the availability of its novel dry eye therapy Lacrifill; and Alcon launches the only multifocal toric contact lens featuring Water Gradient Technology.
Learn more about your ad choices. Visit megaphone.fm/adchoices